All In Biotech

Drug Trial Radar · NCT03192176

A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)

A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging, Phase 2b Study to Investigate the Efficacy of ESN364 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)

Last checked: Nov 20, 2026Latest source record: Nov 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 356 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

356

Actual

Start

Jul 19, 2017

Primary completion

Sep 19, 2018

Study completion Sep 19, 2018

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jun 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes. The treatment was administered for 12 weeks to postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per week.

Conditions

  • Menopause
  • Hot Flashes

Interventions

  • FezolinetantDrug

    Oral Capsule

  • PlaceboDrug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4Time frame: Baseline and week 4
  2. Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12
  3. Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
  4. Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12

Locations

51 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Los Angeles, California

  • Research Site

    Oceanside, California

  • Research Site

    Panorama City, California

  • Research Site 052

    Sacramento, California

  • Research Site 058

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Valley Village, California

  • Research Site

    Denver, Colorado

  • Research Site

    Milford, Connecticut

  • Research Site

    Crystal River, Florida

  • Research Site

    DeLand, Florida

  • Research Site

    Jupiter, Florida

  • Research Site

    Lake Worth, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Port Saint Lucie, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Norcross, Georgia

  • Research Site

    Meridian, Idaho

  • Research Site

    Champaign, Illinois

  • Research Site

    Marrero, Louisiana

  • Research Site

    Elkridge, Maryland

  • Research Site

    Watertown, Massachusetts

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Norfolk, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    New York, New York

  • Research Site

    Williamsville, New York

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Cleveland, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Mt. Pleasant, South Carolina

  • Research Site

    Clarksville, Tennessee

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.